Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT
is a combination of three drugs - cisplatin, vinblastine, and temozolomide. We and other
investigators have used CVT in melanoma patients and found that tumors got significantly
smaller in 30-40% of cases. In this study, the investigators want to get a precise idea of
how many patients will respond to CVT. Also they want to test which genes in the tumor are
turned on and which are turned off. We hope this will teach us to know in the future which
tumors will respond to CVT.